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Abstract 
X-linked agammagiobulinemia (XLA) is an inherited immunodeficiency disease associated with a block in differentiation from pre-B to B cells. 
The XLA gene encodes a 659 amino acids cytoplasmic protein tyrosine kinase named btk (Bruton's tyrosine kinase). The few btk gene alterations 
so far reported in XLA patients are heterogenous and distributed in all domains of the btk protein. They appear to be responsible for a range of 
B call immunodeficieney disorders of variable severity. Rare families in which XLA is inherited together with isolated growth hormone deficiency 
(IGHD) have been reported. Genetic analysis has shown that this disease association maps to the same region of the X chromosome as XLA, but 
whether the two phenotypes are caused by a common or different developmental or biochemical mechanism is unknown. We have analysed the btk 
gene of a patient with XLA and IGHD. RT-PCR analysis of btk transcripts, equencing data obtained from eDNA and genomic DNA and in vitro 
splicing assays howed that an intronic point mutation (1882 + 5G--->A) is responsible for skipping of an exon located in the tyrosine kinase domain. 
This exon-skipping event results in a frameshift leading to a premature stop codon 14 amino acids downstream, and in the loss of the last 61 residues 
of the earboxy-terminal end of the protein. Although we studied a sporadic ase, the results uggest that an alteration of the btk gene might cause 
this unusual phenotype. 
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1. Introduction 
X-linked agammaglobulinemia (XLA) is an inherited 
immunodeficiency disease that affects males, who are 
generally identified by their unusual susceptibility obac- 
terial infections [1]. XLA patients have very low serum 
levels of all immunoglobulin classes, their plasma cells 
are virtually absent and B ceils are almost undetectable 
in lymphoid tissues, where they mature, or in the blood 
stream [2,3]. However, the number of pre-B cells in bone 
marrow is normal [4] and T cells are apparently unaf- 
fected. The causative defect seems to prevent ransition 
of pre-B cells into B cells. Female obligate carriers of 
XLA appear to be immunologically normal, but X chro- 
mosome inactivation is not random in B lymphocytes, 
probably because the B cell in which the XLA-bearing 
chromosome is active cannot mature [5-7]. This feature 
enables female carriers to be identified in affected fami- 
lies [5]. 
The XLA gene, which is contained in the mid portion 
of the long arm of the X chromosome atXq21.3-Xq22 
[8-13], has recently been isolated by positional cloning 
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[14] and as a cDNA clone in a library derived from 
murine B-cell progenitors [15]. The cloned gene encodes 
a 659 amino acid cytoplasmic protein tyrosine kinase 
named btk (Bruton's tyrosine kinase) which is expressed 
in B lymphocytes and myeloid cells as well as in lung and 
pancreas, but not in the T cell lineage. Sequence analysis 
of btk has revealed homologies with the Drosophila 
melanogaster Dsrc28C kinase, tecI and teclI mammalian 
kinases, itk murine kinase [15] and the recently identified 
EMT human kinase expressed mainly in T lymphocytes 
and in natural killer cells [16]. All members of this new 
family of intracellular protein tyrosine kinases hare the 
following characteristics: (1)a large unique amino termi- 
nal region lacking myristylation sites, (2) two src homol- 
ogy (SH) regulatory domains, SH2 and SH3, (3) a highly 
conserved tyrosine kinase domain containing an ATP- 
binding site and a substrate-specific domain, and (4) a 
short carboxy terminus lacking the negative regulatory 
tyrosine residue found in src family members (Fig. lc). 
The few btk gene alterations reported so far in XLA 
patients include small and large deletions, insertions, and 
a few missense and stop defects [14,17,18]. These muta- 
tions have been identified in all domains of the btk pro- 
tein, and appear to be responsible for a range of B cell 
immunodeficiency disorders of variable severity. 
There have been rare reports of families in which X- 
linked agammaglobulinemia is inherited together with 
isolated growth hormone deficiency (IGHD) [19-21]. 
Examination of X chromosome inactivation and genetic 
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linkage analysis in these families have shown that the 
disease association maps to the same region of the X 
chromosome as Bruton's disease [22]. It is not known 
whether the btk gene itself or if mutations in another 
gene located in the vicinity of the XLA locus account for 
this complexe phenotype. We analyzed the btk gene of 
a patient with both classical XLA and IGHD (peak hGH 
responses of <5 ng/ml hGH to various provocative 
tests). We found that an intronic point mutation causes 
skipping of an exon located in the kinase domain, and 
leads to truncation of the carboxyterminal part of the btk 
protein. These results suggest that alterations of the btk 
gene may cause the unusual mixed disease phenotype. 
2. Materials and methods 
2.1. Patient 
The male patient belongs to a large family with no history of immu- 
nodeficiency or short stature. XLA was diagnosed at 2 years of age, 
when he was seen for recurrent bacterial infections. He had severe 
hypogammaglobulinemia, withIgM levels of 0.05 mg/ml (normal range 
0.54-1.14 mg/ml), IgG of 0.08 mg/ml (6.1-10.7 mg/ml) and IgA of 0.05 
mg/ml (0.46-1.1 mg/ml). He was treated with gammaglobulin infusions. 
Patient growth was normal until 2 years of age, then progressively 
decreased to reach 122 cm (-3.2 SD) at 10.5 years of age. Physical 
examination, including enitalia, was normal. Ornithine and betaxolol- 
glucagon stimulation tests revealed complete GH deficiency with 
plasma GH < 1.7 ng/ml. Other pituitary functions, including TSH, 
PRL, ACTH and gonadotropins, were normal. These data establish the 
diagnosis of isolated severe somatotropic deficiency. The patient, who 
is now 17 years old, is > 3 SD below mean height (155 cm). 
2.2. Nucleic acid purification, reverse transcription and polymerase chain 
reaction amplification 
Total RNA and genomic DNA were purified from Epstein-Barr 
virus-transformed pre-B cells from the patient's bone marrow, and 
B cells from his mother's and a healthy control's peripheral blood, using 
guanidium isothiocyanate and proteinase K treatment, as described in 
[23]. cDNA copies of the btk RNA sequence were synthezised from 10 
ktg of total RNA in a 50/tl reaction mixture containing 10 pmol antis- 
ense primer P2 and AMV reverse transcriptase (Promega Laboratories, 
Madison, WI) in conditions recommended bythe supplier. The cDNA 
and genomic DNA sequences were subjected to amplification essen- 
tially as described by Saiki et al. [24], with 30 cycles (denaturation for 
1 min at 94°C, annealing for 1 min at 550C, and elongation for 90 s 
at 72 ° C). 
The sequences of the oligonucleotides u ed were deduced from the 
published sequence of btk cDNA [14] and numbered according to 
Vetrie et al. [14] except for P7 which was derived from the sequence of 
the 3 kb genomic DNA fragment cloned in this work. 
The primers were as follows: 
PI:5' -GAAAGAAGAAGCTATGGCCGCAG-3'  
P2:5' -TTGGCGAGCTCAGGATTCTTCATCCATG-3'  
P3:5' -CTCCTGAACTACCTGAGGGAG-3'  
P4:5'-TTCAGCAGTCTCACTG-3'  
P5-B:5' -CGCGGATCCGCGGTTTGGTAAACGATCAAGGAG-3'  
P6-B:5' -CGCGGATCCGCGTGTGTTCAGCAGTCTCACTG-3'  
PT:5' -TCATCCTCAGAAACCCTGTG-3'  
2.3. Direct sequencing of PCR-amplified cDNA and genomic DNA 
The sequences of cDNA and genomic DNA samples were deter- 
mined after asymmetric amplification (50 pmol of one primer and 
2 pmol of the other) as described elsewhere [25]. 
2.4. Cloning and sequencing of PCR products 
PCR amplification was performed with oligonucleotides P3 and P4 
on control genomic DNA. The product was subcloned into vector 
pCRII according to the supplier's instructions (TA cloning kit, InVitro- 
gen) and sequenced using the dideoxy chain-termination method. 
2.5. Site-directed mutagenesis and splicing assays 
PCR amplification products were generated from control and patient 
genomic DNA using oligonuciotides P5-B and P6-B, containing a
BamHI site in their 5' ends. After BamHI digestion, they were sub- 
cloned into the BamHI sites of vector pSPL1 (Exon trapping kit, BRL). 
The PCR fragment obtained from the patient's genomic DNA was 
subcloned into vector pCRII and subjected to site-directed mutagenesis 
using the Transformer site-directed mutagenesis kit (Clontech Labora- 
tories) with oligonucleotides P-1882 + 5G (5'-GGGCTTTTGGTAA- 
GTGGATAAGATrACACAG-Y) and pCRII-1880NcollClaI (5'- 
CTCGTCGTGATCGATGGCGATGCC-Y). After mutagenesis, the 
BamHI-digested PCR fragment was subcloned into pSPLh 
Eighty-percent-confluent COS-7 cells were transfected by the 
lipofectine method (Gibco/BRL Life Technology, Grand Island, NY) 
with 2/tg of each pSPL1 recombinant. Approximately 48 h after trans- 
fection, total RNA was extracted [23] reverse transcribed and PCR- 
amplified as described above, with oligonucleotides SD3 and SA4 sup- 
plied with the kit (Exon trapping kit, BRL). 
3. R ~  
3.1. An interstitial deletion in btk mRNA 
The btk gene was analysed in cDNAs prepared from 
RNA extracted from Epstein-Barr virus (EBV)-trans- 
formed pre-B cell lines from the patient and EBV-trans- 
formed B cells lines from his mother and a healthy con- 
trol. In these three individuals, amplification of the 
cDNAs with primers P 1 and P2 generated PCR products 
spanning the whole btk coding region (approximately 
2 kb). Overlapping segments of the coding region were 
amplified to assess the integrity of the btk transcript in 
the patient. The amplification product obtained with ol- 
igonucleotides P3 and P4 was shorter in the patient (262 
bp) than in his mother and the control (381 bp) (Fig. la). 
Sequence analysis of these fragments revealed that the 
shorter transcript lacked nucleotides 1764 to 1882, num- 
bered according to Vetrie et al. [14] (Fig. lb). This dele- 
tion introduces a frameshift that changes 14 amino acids 
and creates apremature stop codon which would lead to 
the loss of the last 61 residues of the carboxy-terminal 
end of the protein (Fig. lc). 
3.2. A mutation in an intron leads to exon skipping 
To characterize the molecular defect at the genomic 
DNA level, we cloned a 3 kb PCR product obtained 
from a control and containing the patient's deleted 
mRNA sequence. Sequence analysis of the clone pro- 
vided information on the intron-exon organization of 
this part of the btk gene. The three introns in this region 
correspond to nucleotides 1698-1699, 1763-1764 and 
1882-1883 (Fig. 2a). The sequence which is deleted from 
the patient's mRNA is a verbatim copy of an entire exon 
(referred to here as exon B), suggesting that the genomic 
defect could lead to skipping of this exon. Comparison 
of the nucleotide sequences of the corresponding 
genomic segments in the patient, his mother and the 
control revealed that exon B is indeed intact in the pa- 
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Fig. 1. Identification of a 119 bp deletion in btk mRNA. (a) RT-PCR 
amplification products from a control (lane 1), the patient's mother 
(lane 2) and the proband (lane 3), using primers P3 and P4. The sizes 
of the PCR products (bp) are indicated on the right. A 100 bp ladder 
(BRL), used as a size marker, is in lane M. (b) Nucleotide sequence 
analysis of the RT-PCR products, using primers P3 and P4, from the 
patient and a healthy control. The sequence was obtained with primer 
P4. (c) Diagram of the btk cDNA and the putative protein from control 
and patient. Primers PI, P2, P3 and P4 are indicated. The encoded 
putative proteins are represented atthe top (control) and at the bottom 
(patient). SH3 and SH2 domains are shown in shaded boxes; tyrosine 
kinase domain is shown in hatched box, ATP-binding site and sub- 
strate-specific domain are denoted by A and B, respectively. The pa- 
tient's eDNA 119 bases deletion leads to a truncated protein missing 
the last 61 residues of the carboxyterminal end of the protein. The 14 
amino acids changed by the frameshift are shown in black box. 
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tient's DNA, but that the splice donor site located on 
the 3' side contains a G-to-A transition at position + 5 
(1882 + 5G--->A) (Fig. 2b). The mutation occurred de 
novo, being absent from the mother's DNA. 
3.3. In vitro analysis of the mRNA processing defect 
To determine whether the 1882 + 5G--->A transition in 
the donor splice site of exon B is sufficient o explain 
skipping of the exon immediately upstream, normal and 
variant RNA splicing were analysed in an in vitro sys- 
tem. A 1.4 kb genomic DNA region was amplified from 
the patient and a normal male with primers P5-B and 
P6-B, to generate DNA segments covering a region en- 
compassed by the 3" end of the upstream exon (A) and 
the 5' part of the downstream exon (C) (Fig. 3a). These 
products were then cloned in the splicing vector pSPL1, 
a plasmid designed to trap coding sequences contained 
in complex genomic DNA. RNA extracted from COS-7 
cells transfected with the pSPL1 recombinants were re- 
verse-transcribed and amplified with PCR primers SD3 
and SA4. Two products of different sizes were obtained: 
a product of 660 bp from the normal pSPL1 recombi- 
nant, and a smaller product (541 bp) from the mutant 
construct (Fig. 3b); the length difference corresponded to 
that of exon B, absent from the patient's mature RNA, 
as confirmed by sequence analyses (data not shown). 
As another mutation in the intron sequences of the 
patient's DNA could cause skipping of exon B, the mu- 
tated sequence was reverted in the mutant clone by 
changing the A at position + 5 into a G. This reversion 
to the wild type restored correct processing of the mRNA 
(Fig. 3b), demonstrating that the 1882 + 5G-->A transi- 
tion is sufficient to induce skipping of exon B. Further- 
more, this mutation perturbed splicing of most of the 
mutant mRNA sequences since the processed transcripts 
appeared homogeneous. 
4. Discussion 
The aim of this study was to understand the molecular 
mechanism underlying the phenotype observed in a pa- 
tient with both typical X-linked agammaglobulinemia 
(XLA) and isolated growth ormone deficiency (IGHD), 
conditions coexisting in rare families [19-21]. In most 
cases, these two disorders are not associated. IGHD seg- 
regates in an autosomal recessive (IGHD I) or dominant 
(IGHD II) fashion due to various alterations inGH gene 
[32] and, in some cases, as an X-linked disease (IGHD 
III). Genetic linkage studies have previously established 
that the locus involved in this disease association maps 
to Xq22, like the XLA locus [22]. Since the patient re- 
ported here is a sporadic ase, we were unable to demon- 
strate that the two diseases were inherited together. It is 
unlikely that the growth hormone deficiency in our pa- 
tient results from an acquired alteration of the pituitary 
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Fig. 2. Nucleotide sequences of the btk gene region corresponding to
the deleted mRNA sequence. (a) Intron--exon organizatio ~ qequence 
analysis of a 3 kb PCR product obtained from control genonuc DNA, 
using primers P3 and P4. Intron and exon sequences are denoted by 
lowercase and uppercase l tters, respectively. Nucleotides in exons are 
numbered according to Vetrie et al. [14]. The G-to-A transition at 
position + 5 of the splice donor site of exon B in the patient's genomic 
DNA is indicated by an arrow. (b) Nucleotide sequences around the 
splice donor site of exon B. The arrow indicates the G-to-A substitution 
at position + 5 of the splice donor site in the patient, as compared to 
the patient's mother and a healthy control. 
gland since other pituitary functions were found normal. 
In addition, the two disorders appeared e novo: they are 
not present in the other members of his large family. The 
characterization of the btk gene, a gene which was re- 
cently shown to be responsible for several XLA cases 
[14,15,17,18] prompted us to seek a possible common 
developmental or biochemical defect at the btk locus 
which would explain the coexistence of antibody and 
growth hormone deficiencies. 
A search for potential gene rearrangements or dele- 
tions in the genomic DNA of this subject by Southern 
blot analysis after regular and pulse-field gel electropho- 
resis yielded an unremarkable restriction pattern (not 
shown). However, careful analysis of the btk gene and 
transcript revealed the existence of a de novo mutation 
at position + 5 of a splice donor site (1882 + 5G--->A) 
that alters normal splicing, removing the tyrosine kinase 
domain exon immediately upstream. As revealed by RT- 
PCR and direct sequencing, this exon skipping event 
alters all the btk transcripts. 
Making use of an in vitro splicing test, we obtained 
evidence that the substituted nucleotide is critical for 
correct maturation of the btk mRNA. The nucleotide at 
position + 5 in the splice donor sites is generally a gua- 
nine in 84% of introns, and an adenine, cytosine or thy- 
mine in the remaining 16% [26]. Several mutations at this 
position have been shown to abolish normal splicing and 
to result in similar exon skipping processes [27-30], but 
given the natural occurrence of an adenine in position 
+ 5 in some of 5' splice sites, it was necessary to demon- 
strate that the sequence variation found in the patient's 
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Fig. 3. In vitro analysis of btk mRNA splicing in transfected COS-7 
cells. (a) Diagram of the genomic DNA fragment amplified with prim- 
ers P5-B and P6-B and cloned into pSPL1. The G-to-A transition is 
denoted by an asterisk. The sequences of the vector are shown in 
hatched boxes. SD and SA indicate the positions of the donor and 
aceeptor splice sites, respectively. Normal and mutant splicing patterns 
are schematically represented and the sizes of the corresponding spliced 
products are indicated. (b) RT-PCR amplification products from COS- 
7 cells RNA prepared after transfection with the various constructs 
corresponding to the patient (lane 1), a control (lane 2) and the patient 
after eversion of the mutation to wild-type by site-directed mutagenesis 
(lane 3). The size of the products is indicated on the right (bp); lane M, 
size marker. 
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DNA indeed led to exon skipping. This was done by 
showing that reversion of the mutant sequence to the 
wild-type restored correct processing of the btk mRNA, 
thereby establishing that the 1882 + 5G to A transition 
induces the splice defect. Skipping of exon B results in 
a truncated btk protein in which the last 61 residues of 
the carboxyterminal end of the protein are deleted. More 
precisely, this deletion removes the second half of the 
substrate-specific domain. This domain contains the ty- 
rosine 551, a residue presumed to be a positive regula- 
tory phosphorylation site also found in the other mem- 
bers of this protein tyrosine kinase family and in the 
members of the src and abl tyrosine kinase families 
[14,16,31]. Such truncation is likely to abolish protein 
function, thereby causing the XLA phenotype. 
Various point mutations, insertions and deletions have 
previously been identified in all domains of the btk pro- 
tein [14,17,18]. Interestingly, in addition to this molecu- 
lar heterogeneity, the XLA phenotype is variable. In- 
deed, besides evere agammaglobulinemia cases, milder 
phenotypes are observed. It is possible that some muta- 
tions, which do not completely abolished btk protein 
function could lead to a milder disease, as suggested by 
Bradley et al. [18]. The mutation described here results 
in the loss of the substrate-specific and C-terminal do- 
mains of the protein, the N-terminal, SH3, SH2 and 
ATP-binding site domains remaining intact. Two muta- 
tions resulting in the loss of the 23 C-terminal residues 
of the protein have been described in patients with severe 
agammaglobulinemia [17,18]. However, as compared to 
the mutation reported in this work, these deletions do 
not alter the substrate-specific region of the tyrosine ki- 
nase domain. 
The association of XLA and isolated growth hormone 
deficiency (IGHD) in this patient is puzzling. Several 
mechanisms have been proposed to explain this complex 
phenotype [22]. Firstly, another gene located in the vicin- 
ity of the btk gene and controlling rowth hormone se- 
cretion could be missing, but deletion of the btk gene 
along with another contiguous gene was ruled out. In 
addition, it is highly unlikely that two independent point 
mutations occurred de novo, one altering the btk gene 
and the other a gene that controls growth, since there is 
no family history of IGHD, and the mutation in the btk 
gene was not found in the mother. Secondly, among 
other possibilities i the existence of another gene located 
in the Xq21.3--q22 region, encoding a factor involved in 
both the control of pre-B cell maturation and growth 
hormone expression. However, our results dearly dem- 
onstrate that the btk gene mutation is responsible for the 
XLA phenotype in this patient. A third possibility is that 
some mutant forms of the btk gene could give rise to 
XLA alone, while other mutants could generate both 
XLA and IGHD. If this were the case, the btk gene 
would probably be expressed in the pituitary gland 
where GH is produced. To test this hypothesis, 30 cycles 
of RT-PCR were carried out on mRNA from pituitaries, 
and the product was sequenced. This led to the detection 
of a specific btk amplification product of expected size 
and sequence (data not shown). It is thus tempting to 
speculate that the protein tyrosine kinase encoded by the 
btk gene could play a role in the biosynthesis or secretion 
of growth hormone, and that some mutant forms of the 
btk protein could impair both the production of growth 
hormone and the development of B lineage cells. Char- 
acterisation of additional btk gene mutations in the rare 
patients inheriting both XLA and IGHD is eagerly 
awaited. 
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